Stephenson Harwood advised Dr. Falk on the deal. Dr. Falk Pharma GmbH completed the acquisition of Kynos Therapeutics Ltd, a clinical stage biopharmaceutical company focusing on...
You must be a Standard 1 Year member to access this content.
Stephenson Harwood advised Industrial Physics on acquisition of Torus Technology. Industrial Physics has acquired Torus Technology Group from multiple individual sellers. Industrial Physics, a global provider...
You must be a Standard 1 Year member to access this content.
Stephenson Harwood and Akerman LLP advised Iluma Alliance on the acquisition of Anitox Group. Iluma Alliance made the acquisition of Anitox Group. Iluma Alliance is a...
You must be a Standard 1 Year member to access this content.
On the deal, Travers Smith acted for V.Group, Kirkland & Ellis advised Advent International, and Mayer Brown advised the consortium. Stephenson Harwood advised V.Group and Advent...
You must be a Standard 1 Year member to access this content.
Ashurst advised Volac International Limited on the deal. Stephenson Harwood LLP has advised the Denkavit Group on its acquisition. Volac International Limited, a world leader in...
You must be a Standard 1 Year member to access this content.
Stephenson Harwood advised Novacyt on Yourgene Health takeover. Novacyt UK, a diagnostics company, has agreed to acquire UK-based genomic medicine firm Yourgene Health in a £16.7...
You must be a Standard 1 Year member to access this content.
Stephenson Harwood advised BenevolentAI on strategic collaboration with Merck. BenevolentAI has entered into a strategic collaboration with Merck. This collaboration will leverage BenevolentAI’s comprehensive AI platform...
You must be a Standard 1 Year member to access this content.
Stephenson Harwood advised Bicycle Therapeutics on radiotherapy deal with Bayer. Bayer and Bicycle Therapeutics plc have announced a strategic collaboration agreement to develop, manufacture, and commercialize...
You must be a Standard 1 Year member to access this content.
Stephenson Harwood LLP has advised Oxford Biomedica on the deal. Oxford Biomedica, the gene and cell therapy company, on its new three year Master Services &...
You must be a Standard 1 Year member to access this content.
Stephenson Harwood has advised Hipgnosis Song Management on the deal, while Kirkland & Ellis has advised funds managed by Blackstone. Hipgnosis Song Management (HSM) signed a...
You must be a Standard 1 Year member to access this content.
Stephenson Harwood LLP has advised AM-Pharma on the deal. AM-Pharma signed a €245 million exclusive license agreement deal with Kyowa Kirin, for the development and commercialisation...
You must be a Standard 1 Year member to access this content.
Stephenson Harwood LLP has advised Kroll on the deal. Taylor Wessing advised the sellers. Kroll, a global provider of services and digital products related to governance,...
You must be a Standard 1 Year member to access this content.
